PMID- 30643403
OWN - NLM
STAT- MEDLINE
DCOM- 20190212
LR  - 20220331
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 14
DP  - 2019
TI  - Combination of doxorubicin liposomes with left atrial appendage radiofrequency 
      catheter ablation to reduce post-ablation recovery of electrical conduction.
PG  - 231-241
LID - 10.2147/IJN.S186267 [doi]
AB  - AIMS: To determine whether use of radiofrequency catheter ablation (RFCA) 
      combined with intravenously administered liposomal doxorubicin (L-DOX) 
      facilitates a reduction in the recovery of post-ablation electrical conduction. 
      METHODS: Circumferential ablation was performed on the epicardial surface of the 
      left atrial appendage (LAA) in New Zealand White rabbits, and L-DOX was then 
      administered intravenously. Fluorescence spectrophotometry was used to assess 
      reagent bio-distribution, while Western blots and immunohistochemistry were used 
      to assess the localization of the apoptotic markers Bcl-2, Bax, and cleaved CASP3 
      in the LAA. Liver, kidney, and cardiac functions were also measured to evaluate 
      the safety of this approach. RESULTS: At 1 week and 1 month after RFCA, a pacing 
      electrocardiogram could not be detected in most of the rabbits that had received 
      the combined RFCA and L-DOX therapy. L-DOX began to target the LAA on the second 
      day after RFCA. L-DOX treatment increased the apoptosis of cardiomyocytes in the 
      regions peripheral to the necrotic area induced by RFCA. Doxorubicin had some 
      effect on liver and kidney function, but these effects were reversible and did 
      not affect survival. CONCLUSION: The present results provide evidence that L-DOX 
      treatment can reduce the recovery of electrical conduction after RFCA therapy 
      owing to L-DOX-induced apoptosis of cardiomyocytes in the ablated area and the 
      proximal transition zone of the LAA.
FAU - Zhuge, Ying
AU  - Zhuge Y
AD  - Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200800, People's Republic of China, 
      onlyfang1@hotmail.com.
FAU - Ni, Huan-Er
AU  - Ni HE
AD  - Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200800, People's Republic of China, 
      onlyfang1@hotmail.com.
FAU - Wang, Yu-Jie
AU  - Wang YJ
AD  - Department of Pharmaceutics, School of Pharmacy, East China University of Science 
      and Technology, Shanghai 200237, People's Republic of China.
FAU - He, Mu-Ye
AU  - He MY
AD  - Department of Pharmaceutics, School of Pharmacy, East China University of Science 
      and Technology, Shanghai 200237, People's Republic of China.
FAU - Wang, Jun-Shan
AU  - Wang JS
AD  - Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji 
      University, Shanghai 200072, People's Republic of China.
FAU - Gao, Feng
AU  - Gao F
AD  - Department of Pharmaceutics, School of Pharmacy, East China University of Science 
      and Technology, Shanghai 200237, People's Republic of China.
AD  - Shanghai Key Laboratory of Functional Materials Chemistry, East China University 
      of Science and Technology, Shanghai 200237, People's Republic of China.
FAU - Wang, Fang
AU  - Wang F
AD  - Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200800, People's Republic of China, 
      onlyfang1@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20181227
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (liposomal doxorubicin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/*administration & dosage
MH  - Atrial Appendage/*physiopathology
MH  - Atrial Fibrillation/etiology/*prevention & control/surgery
MH  - Catheter Ablation/*adverse effects
MH  - Doxorubicin/administration & dosage/*analogs & derivatives
MH  - Female
MH  - Male
MH  - Polyethylene Glycols/administration & dosage
MH  - Postoperative Complications/*prevention & control
MH  - Rabbits
MH  - Treatment Outcome
PMC - PMC6312058
OTO - NOTNLM
OT  - atrial fibrillation
OT  - doxorubicin
OT  - liposome
OT  - radiofrequency catheter ablation
OT  - recovered electrical conduction
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2019/01/16 06:00
MHDA- 2019/02/13 06:00
PMCR- 2018/12/27
CRDT- 2019/01/16 06:00
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/02/13 06:00 [medline]
PHST- 2018/12/27 00:00 [pmc-release]
AID - ijn-14-231 [pii]
AID - 10.2147/IJN.S186267 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2018 Dec 27;14:231-241. doi: 10.2147/IJN.S186267. eCollection 
      2019.